Фромилид is commonly used to help manage symptoms associated with specific bacterial infections. This medicine may provide relief across various body systems by addressing the underlying susceptible bacterial cause of conditions. Its primary role is to support the body's recovery from infections affecting the respiratory tract, skin, and soft tissues.

Approved clinical uses for Фромилид include infections of the upper and lower respiratory tract, such as certain cases of acute bacterial sinusitis, community-acquired pneumonia, and exacerbations of chronic bronchitis; skin and soft tissue infections; and specific ear and throat infections.

“This medication is intended to offer symptom relief and support recovery from specific bacterial infections.”

Фромилид may help reduce the duration and severity of uncomfortable symptoms like fever, pain, and inflammation related to these conditions. Always consult a healthcare professional for a precise diagnosis and personalized treatment plan.

Quick Fact: Relief for Bacterial Respiratory Symptoms

Clarithromycin (Фромилид) eligibility is determined by specific regulatory criteria regarding age, organ function, and concurrent medication use.

Contraindicated Populations

Use is absolutely prohibited for patients with a known macrolide allergy, a history of QT prolongation or ventricular cardiac arrhythmias (including Torsades de Pointes), and those with severe hepatic failure combined with renal impairment.

Use is also contraindicated when taking specific high-risk medications, including lovastatin, simvastatin, pimozide, cisapride, ergot alkaloids (e.g., ergotamine), ticagrelor, or ranolazine.

---

Age-Related and Condition-Specific Eligibility

Population	Regulatory Status
Infants (< 6 months)	Safety and efficacy are not established by regulators.
Children (6 months–12 years)	Eligible for use, typically using the oral suspension formulation.
Severe Renal Impairment	Dosage must be reduced by one-half when creatinine clearance is less than 30 mL/min.
Impaired Hepatic Function	Caution is required, as the liver is the principal site of metabolism.

Pregnancy and Lactation

The medicine is not advised in pregnant women, particularly during the first trimester, unless the benefit outweighs the potential risk and no suitable alternative is available. Clarithromycin is excreted into human breast milk, and use is generally not recommended.

Interactions with other medicines and products

mathbfФромилид (mathbfClarithromycin) is officially documented as a strong inhibitor of Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). This pharmacokinetic interaction reduces the clearance of many co-administered drugs, leading to increased systemic exposure and potential toxicity.

Strictly Contraindicated Combinations

Regulatory agencies prohibit the co-administration of mathbfФромилид with specific medicines due to severe interaction risks:

• Cardiac Risks: Astemizole, Cisapride, Pimozide, Terfenadine, and Domperidone are prohibited due to the risk of QT prolongation and Torsades de Pointes.
• Myopathy Risk: mathbfClarithromycin is contraindicated with CYP3A4-metabolized statins, specifically Lovastatin and Simvastatin, due to the heightened risk of rhabdomyolysis.
• Acute Toxicity: Ergotamine and Dihydroergotamine are prohibited due to the risk of acute ergot toxicity, and Colchicine is contraindicated in patients with renal or hepatic impairment.

Other Clinically Significant Interactions

Concomitant use with oral anticoagulants, such as Warfarin, may result in elevated INR/prothrombin time and increased risk of serious hemorrhage. Additionally, co-administration with oral hypoglycemic agents or insulin may lead to significant hypoglycemia. For the antiretroviral Zidovudine, the regulatory constraint requires doses to be administered at least 2 hours apart. The extended-release formulation mathbfmust be taken with food, a condition necessary to maintain proper drug absorption.

Core Mechanistic Domain: Inhibiting Bacterial Replication

Фромилид ( Кларитромицин) functions by achieving high-affinity, reversible binding to the bacterial 50S ribosomal subunit, specifically at the 23S ribosomal RNA ( rRNA) component. This interaction acts as an inhibitor, physically blocking the Nascent Peptide Exit Tunnel (NPET). This blockade prevents the translocation of transfer RNA, leading to the immediate termination of the polypeptide chain and, consequently, the cessation of essential bacterial protein synthesis (mathbfbacteriostasis).

Dual Action and Modulation of Host Systems

Functional efficacy is enhanced by the primary active metabolite, 14-hydroxyclarithromycin, which operates via the same ribosomal blockade mechanism, resulting in a synergistic inhibition of protein synthesis. Additionally, Кларитромицин engages a secondary mechanism by modulating local inflammatory pathways, influencing the release of pro-inflammatory messengers like IL-8. The drug’s action can be functionally compromised when bacteria develop ribosomal methylation (via erm genes) or when efflux pumps (via mef genes) actively expel the compound, reducing the concentration below the inhibitory threshold required at the 50S ribosomal target.

Administration and Dosing Guidelines

Фромилид (Clarithromycin) is administered via the oral route using film-coated tablets or granules for suspension, though an intravenous (I.V.) formulation exists for severe, acute settings, typically for 2 to 5 days before transitioning to oral therapy. Administration procedures follow established clinical protocols.

Standard Dosing and Frequency

For most infections, the standard adult dose of the immediate-release tablet is 250 mg to 500 mg taken every 12 hours (twice daily). The usual treatment duration is 7 to 14 days. Specific regimens, such as for H. pylori eradication, may involve 500 mg taken every 8 or 12 hours in combination with other agents for 10 to 14 days.

Administration Instructions

• Oral Intake: Immediate-release tablets and oral suspension can generally be taken with or without food. However, the extended-release form is taken with food.
• Suspension: The granules are reconstituted with water and the suspension is shaken well before each measured dose.
• I.V. Infusion: The intravenous form is given as a slow infusion over 60 minutes; bolus or intramuscular injection is not used.

Population-Specific Use

• Pediatric Patients: The oral suspension is typically used for children under 12 years of age, with the dose calculated based on the child's body weight (e.g., 7.5 mg/kg every 12 hours). Tablets are generally not used for this age group.
• Renal Impairment: For patients with severe kidney impairment (creatinine clearance < 30 mL/min), the total daily dose is typically reduced by one-half.

Evidence for Use in Respiratory Tract Infections and Skin Infections

Clarithromycin was studied for conditions such as Community-Acquired Pneumonia (CAP) and periods of heightened symptoms associated with chronic bronchitis. These evaluations included Randomized Controlled Trials (RCTs) and systematic reviews, which primarily monitored outcomes related to symptom intensity or variability and physiological strain or stress. The medicine was also examined as a component of combination therapy in studies conducted on hospitalized adults. For mild to moderate skin and soft tissue infections, the medicine was evaluated in comparative trials and specialized studies assessing the drug's concentration at the site of infection. Findings describe patterns observed in the studied populations.

---

️ Evidence for Use in Helicobacter pylori Eradication

Clarithromycin was studied for H. pylori infection, which is often associated with duodenal ulcer conditions. Research primarily focused on RCTs comparing multi-drug regimens, assessing measurements related to bacterial presence after study completion. Evidence suggests patterns related to the specific combination of medicines and was observed in some studies to be influenced by the local prevalence of bacterial resistance. Research does not determine whether an individual will respond similarly and results apply only to the populations studied.

---

‍️ Evidence Gaps and Special Populations

Studies monitored outcomes in adults, older adults, and pediatric patients for conditions like acute ear or throat infections. Evidence is limited regarding long-term outcomes specifically in non-cardiac populations. Follow-up durations were limited in many key studies, meaning the evidence contributes to understanding short-term symptom patterns but offers less insight into sustained changes. The applicability of older study results may be uncertain as bacterial resistance patterns evolve, and subgroup findings are uncertain for certain comorbidity groups.

Key Studies & References

1. Label: CLARITHROMYCIN tablet - DailyMed (Official FDA-approved indications and study summaries)
2. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection (Source for resistance/combination therapy evidence)
3. Add-on clarithromycin improves community-acquired pneumonia outcomes (Example RCT/Meta-analysis summary for CAP/combination therapy)
4. Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies - PubMed (Multicenter trial example for SSI)
5. Community-Acquired Pneumonia (CAP) - Medscape Reference (Source for general CAP treatment strategy and resistance context)

Common questions about Фромилид (FAQ)

---

Q: What is Фромилид used for?

A: Фромилид (clarithromycin) is a macrolide antibiotic used to address various bacterial infections. This may include infections of the skin, ears, sinuses, respiratory tract (like bronchitis and pneumonia), and in combination with other agents, for Helicobacter pylori infection linked to stomach ulcers.

---

Q: What is the most important thing I should know before taking Фромилид?

• Allergies: Inform your healthcare provider if you have any known allergy to clarithromycin or other macrolide antibiotics (such as azithromycin or erythromycin).
• Contraindications: This medication is not typically used if you have a history of certain severe liver problems or a known history of prolonged QT interval (a heart rhythm condition). There are also specific medications that should not be taken with Фромилид due to the risk of serious side effects.
• Drug Interactions: Tell your healthcare provider about all medications you are currently taking, including prescription drugs, over-the-counter products, and supplements, as clarithromycin interacts with many other drugs. This includes, but is not limited to, certain cholesterol-lowering drugs (statins) and medications for irregular heart rhythms.

---

Q: What are the possible side effects of Фромилид?

A: Like many medications, Фромилид may be associated with side effects. Common observed effects can include:

• Changes in taste (often metallic or unpleasant)
• Diarrhea
• Nausea and vomiting
• Stomach pain
• Headache

Serious, but less common, side effects have been reported, which may require immediate medical attention. These include signs of a serious allergic reaction, severe diarrhea (which may occur up to two months after stopping the medication), liver problems (such as yellowing of the skin or eyes), and effects on heart rhythm, particularly in individuals with pre-existing heart conditions or low potassium/magnesium levels.

---

Q: Is it safe to use Фромилид during pregnancy?

A: The use of clarithromycin during pregnancy is generally not recommended unless a healthcare provider determines there is no suitable alternative and the potential benefit justifies the potential risks. Animal studies suggest a potential for harm, though human data is limited. If you are pregnant, planning to become pregnant, or become pregnant while taking this medication, you should consult your healthcare provider immediately to discuss the potential risks.

---

Q: Can Фромилид be used to treat viral infections like the common cold?

A: No. Фромилид is an antibiotic and is effective only against specific types of bacteria. It is not used to treat infections caused by viruses, such as the common cold or the flu. Taking an antibiotic for a viral infection is not helpful and may contribute to antibiotic resistance.

Storage and Handling Requirements

Фромилид (Clarithromycin) must be stored strictly according to regulatory specifications to maintain its stability. Tablets must be kept at controlled room temperature (20 C to 25 C or 68 F to 77 F) and protected from light.

The reconstituted oral suspension has distinct constraints: it must not be refrigerated or frozen, and any unused portion must be discarded after 14 days.

All forms must remain in the original, tightly closed container, and be stored away from excessive heat and moisture. To ensure household safety, the medicine must be kept out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Фромилид should be disposed of through a drug take-back program. If this is unavailable, it must be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container for household trash; it is not to be flushed down the toilet or poured into the drain.